Source86

Source86 is an early-stage biotechnology company focused on the discovery and development of a new class of small molecule therapeutics targeting the "undruggable" proteome. Founded by renowned chemical biologists Kevan Shokat and Jack Taunton from UCSF, the company utilizes a proprietary platform that combines structural biology, chemical proteomics, and machine learning to identify and exploit cryptic pockets in high-value disease targets. Source86 specifically focuses on covalent drug discovery to achieve high selectivity and potency against targets that have traditionally lacked well-defined binding sites. The company's approach aims to address significant unmet needs in oncology and immunology by expanding the range of proteins accessible to small molecule intervention.